Unlike other cancer subtypes like non-small cell lung cancer (NSCLC), bladder, or renal cell cancer, combinatorial approaches of chemoimmunotherapy or adding VEGF inhibitors or local ablation to immunotherapy can result in improved outcomes for patients with CCA. The gene discussed is VEGFA; the disease is cholangiocarcinoma.